This clinical trial is focused on studying a condition called neovascular age-related macular degeneration (nAMD), which affects the eyes and can lead to vision loss. The study will compare two treatments: RBS-001 and Eylea. Both treatments involve a medication called aflibercept, which is used to help manage this eye condition. Aflibercept works by blocking a protein that can cause abnormal blood vessel growth in the eye, which is a key problem in nAMD.

The purpose of the study is to see if RBS-001 is as effective and safe as Eylea in treating nAMD. Participants in the study will receive injections of either RBS-001 or Eylea directly into the eye, a method known as intravitreal use. The study will also use a substance called fluorescein sodium to help doctors see the blood vessels in the eye more clearly during certain tests. This is done through a process called fluorescence angiography, which involves injecting fluorescein sodium into a vein to highlight the blood vessels in the eye.

Throughout the study, participants will have their vision tested regularly to monitor changes. The main focus will be on the change in vision clarity, measured by a test called the ETDRS letter score, at different points in time, especially at 8 weeks after starting treatment. The study will last for up to 52 weeks, with regular check-ups to ensure the safety and effectiveness of the treatments. The goal is to determine if RBS-001 can provide similar benefits to Eylea for people with nAMD.